Amneal receives u.s. fda tentative approval for beclomethasone dipropionate hfa inhalation aerosol

Bridgewater, n.j., oct. 29, 2025 (globe newswire) -- amneal pharmaceuticals, inc. (“amneal” or the “company”) today announced that the u.s. food and drug administration (fda) has tentatively approved the company's abbreviated new drug application (anda) for beclomethasone dipropionate hfa inhalation aerosol (40 mcg/actuation and 80 mcg/actuation).
AMRX Ratings Summary
AMRX Quant Ranking